Key facts
- Autolomous’s last known valuation is $29.5M (Sep 2024).
- It has raised $12.8M; the latest was Later Stage VC ($4.4M) in Mar 2025.
- Notable investors include Innovate UK, MedTech Innovator, BioTools Innovator, Aescuvest, CMS equIP — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Autolomous
- ·The full record, as it builds
Funding rounds
No funding rounds for Autolomous are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Autolomous
Developer of a healthcare manufacturing data management platform intended to support the development and delivery of advanced medicines. The company offers laboratory-friendly software that securely transfers manufacturing data to a cloud-based system with immutable data tracking, scheduling tools, and digital quality approvals, enabling therapy developers to manage manufacturing processes efficiently and improve the accessibility of advanced medicines.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 37
- Website
- autolomous.com/
- Ownership
- Privately Held (backing)
Autolomous doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Autolomous shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Autolomous in its N-PORT filings yet. We sweep new filings monthly.